Monitoring the in vivo siRNA release from lipid nanoparticles based on the fluorescence resonance energy transfer principle

Sun, Lei; Zhang, Jinfang; Zhou, Jinge; Wang, Jing; Wang, Zhehao; Luo, Shenggen; Wang, Yeying; Zhu, Shulei; Yang, Fan; Tang, Jie; Lü, Wei; Wang, Yiting; Yu, Lei; Yan, Zhiqiang

doi:10.1016/j.ajps.2022.11.003

Cited by 4 publications

(2 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, monitoring of in vivo release and distribution of siRNA is still challenging. To improve monitoring, the use of different imaging techniques, such as fluorescence imaging and CT imaging, may be an effective approach [ 127 ].…”

Section: Conclusion and Future Perspectivementioning

confidence: 99%

Advances with Lipid-Based Nanosystems for siRNA Delivery to Breast Cancers

2023

View full text Add to dashboard Cite

Breast cancer is the most frequently diagnosed cancer among women. Breast cancer is also the key reason for worldwide cancer-related deaths among women. The application of small interfering RNA (siRNA)-based drugs to combat breast cancer requires effective gene silencing in tumor cells. To overcome the challenges of drug delivery to tumors, various nanosystems for siRNA delivery, including lipid-based nanoparticles that protect siRNA from degradation for delivery to cancer cells have been developed. These nanosystems have shown great potential for efficient and targeted siRNA delivery to breast cancer cells. Lipid-based nanosystems remain promising as siRNA drug delivery carriers for effective and safe cancer therapy including breast cancer. Lipid nanoparticles (LNPs) encapsulating siRNA enable efficient and specific silencing of oncogenes in breast tumors. This review discusses a variety of lipid-based nanosystems including cationic lipids, sterols, phospholipids, PEG-lipid conjugates, ionizable liposomes, exosomes for effective siRNA drug delivery to breast tumors, and the clinical translation of lipid-based siRNA nanosystems for solid tumors.

show abstract

Section: Conclusion and Future Perspectivementioning

confidence: 99%

Advances with Lipid-Based Nanosystems for siRNA Delivery to Breast Cancers

2023

View full text Add to dashboard Cite

show abstract

“…Sun et al. [142] coupled Cy5-modified survivin siRNA to AuNPs and then coated with lipid NPs (Au-DR-siRNA@LNPs). Au-DR-siRNA@LNPs not only successfully inhibited tumor cell survival protein expression, but also enabled fluorescence imaging and CT imaging to monitor the behavior of siRNA in vivo .…”

Section: Delivery Vector-assisted Sirna Drugs For Tme Modulationmentioning

confidence: 99%

Remodeling the tumor immune microenvironment via siRNA therapy for precision cancer treatment

Jiang,

Qi,

Yang

et al. 2023

Asian Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

Theranostic Lipid Nanoparticles for Renal Cell Carcinoma

Mao,

Wang,

Wang

et al. 2023

Advanced Materials

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) is a common urological malignancy and represents a leading threat to healthcare. Recent years have seen a series of progresses in the early diagnosis and management of RCC. Theranostic lipid nanoparticles (LNPs) are increasingly one of the focuses in this field, because of their suitability for tumor targeting and multimodal therapy. LNPs can be precisely fabricated with desirable chemical compositions and biomedical properties, which closely match the physiological characteristics and clinical needs of RCC. Herein, a comprehensive review of theranostic LNPs is presented, emphasizing the generic tool nature of LNPs in developing advanced micro‐nano biomaterials. It begins with a brief overview of the compositions and formation mechanism of LNPs, followed with an introduction to kidney‐targeting approaches, such as passive, active, and stimulus responsive targeting. With examples provided, a series of modification strategies for enhancing the tumor targeting and functionality of LNPs were discussed. Thereafter, research advances on applications of these LNPs for RCC including bioimaging, liquid biopsy, drug delivery, physical therapy, and gene therapy are summarized and discussed from an interdisciplinary perspective. The final part highlights the milestone achievements of translation medicine, current challenges as well as future development directions of LNPs for the diagnosis and treatment of RCC.This article is protected by copyright. All rights reserved

show abstract

Monitoring the in vivo siRNA release from lipid nanoparticles based on the fluorescence resonance energy transfer principle

Cited by 4 publications

References 39 publications

Advances with Lipid-Based Nanosystems for siRNA Delivery to Breast Cancers

Advances with Lipid-Based Nanosystems for siRNA Delivery to Breast Cancers

Remodeling the tumor immune microenvironment via siRNA therapy for precision cancer treatment

Theranostic Lipid Nanoparticles for Renal Cell Carcinoma

Contact Info

Product

Resources

About